Injury guide

Vision Loss After Ozempic: Get an Eye Check

Lost sight or noticed a sudden change while using Ozempic? Seek eye care right away.

See If You Qualify

Free · No obligation · About 2 minutes

Updated Oct 4, 202618 sources

This may apply to you if

  • Tell the lawyer the exact drug you used and when you used it.
  • Bring the gut diagnosis and test results in your medical chart.
  • Describe symptoms before and after the drug, including other health problems.

What the public record says

These are cited sources. Their inclusion does not imply that they endorse People’s Justice or reviewed this page.

The evidence and its limits

Massachusetts Eye and Ear, Harvard Medical School · JAMA Ophthalmology · 2024

Semaglutide and NAION in patients at one neuro-ophthalmology service

Design:
Cohort
Participants:
Registry of 16,827 without prior NAION; reported diabetes group of 710 and overweight/obesity group of 979. Not one pooled count of treated or matched patients.
Finding:
Higher NAION incidence was associated with semaglutide in the selected patient comparisons.
Main limitation
Retrospective selected single-center population; association does not establish cause or a personal risk estimate. Original author abstract and metadata read, full paper not reviewed.

Read the source: Semaglutide and NAION in patients at one neuro-ophthalmology service (opens in a new tab) · Checked Oct 3, 2026

European Medicines Agency · 2025

PRAC semaglutide–NAION safety review

Design:
Agency review
Participants:
No recruited cohort count supplied by the notice; regulatory review of available data.
Finding:
The committee concluded NAION is a very rare side effect of semaglutide and recommended updated EU product information.
Main limitation
Regulatory review of semaglutide, not proof of identical risk for every GLP-1 or dual-agonist drug or cause in an individual legal claim.

Read the source: PRAC semaglutide–NAION safety review (opens in a new tab) · Checked Oct 3, 2026

The short answer

What is a vision-loss concern?
Sight can change for many reasons. NAION is one type of optic nerve injury. A doctor should assess what happened in your eye. [14]
When should I see an eye doctor?
Seek care right away for sudden sight loss. Do not wait for a lawyer or an online review. The cause may need urgent medical attention. [15]
How is the condition diagnosed and treated?
Tell the clinician what changed and when. Ask what the eye exam shows. Testing and care depend on the actual condition, not a website’s claim label. [14]
What does the drug evidence establish?
A study and a European review discuss semaglutide and NAION. They do not diagnose a new symptom in you. They do not establish equal risks for all drugs. [16]

What rules a case out

Not covered by this case

  • A symptom does not establish an NAION diagnosis.
  • Different eye diseases are not one legal or medical condition.
  • No test, drug change or personal risk forecast is supplied.

The process

What happens next

  1. 01

    You answer a few questions

    About two minutes. Nothing is sent until you agree on the last step and press submit.

  2. 02

    A lawyer looks at it

    A lawyer at the firm reads your answers and checks them against the current case criteria.

  3. 03

    The firm decides and gets in touch

    If the firm takes your case, you get the terms in writing to read before you sign. You can always say no.

When it fits this case

  • Tell the lawyer the exact drug you used and when you used it.
  • Bring the gut diagnosis and test results in your medical chart.
  • Describe symptoms before and after the drug, including other health problems.
  • Ask how the relevant law and your dates affect whether a claim can proceed.

Lost sight or noticed a sudden change while using Ozempic? Seek eye care right away. A doctor should find the cause before you label the problem for a claim.

What is a vision-loss concern?

Sight can change for many reasons. NAION is one type of optic nerve injury. A doctor should assess what happened in your eye.

The specialist brochure describes reduced blood flow at the front of the optic nerve in NAION. The Ozempic label separately discusses diabetic retinopathy. A broad vision-loss label cannot determine which condition you have.

When should I see an eye doctor?

Seek care right away for sudden sight loss. Do not wait for a lawyer or an online review. The cause may need urgent medical attention.

MedlinePlus lists sudden loss among serious vision changes requiring prompt eye care. A painless change can still need assessment. A legal intake form cannot perform an eye examination.

How is the condition diagnosed and treated?

Tell the clinician what changed and when. Ask what the eye exam shows. Testing and care depend on the actual condition, not a website’s claim label.

For suspected NAION, the society brochure describes a clinical judgment using several findings and checking other causes. Its treatment discussion has important limits. An eye doctor should advise your care rather than a general legal page supplying medicines or a prognosis.

What does the drug evidence establish?

A study and a European review discuss semaglutide and NAION. They do not diagnose a new symptom in you. They do not establish equal risks for all drugs.

The Hathaway study abstract reports an association in selected specialist-center comparisons. It does not show that every vision change after semaglutide is NAION or drug-caused. Selection and retrospective records limit the finding.

The European committee’s June 2025 semaglutide finding is separate from the U.S. label’s diabetic-retinopathy warning. Keep the condition, medicine and regulator clear when reading a headline.

Who may qualify for a claim review after an eye exam?

Have harm and a drug history you want checked? Give a lawyer the exact eye report. A symptom or prescription alone does not decide a claim.

The NAION court group is distinct from the gut case group. Its transfer order coordinates cases; it does not diagnose every reader or determine personal liability. Ask which alleged injury and claim, if any, match your records.

What records and next steps help after care?

Keep your eye report, symptom dates and medicine history. Ask about the legal time limit and fees. Check who will handle any files you share.

Ask the covered provider for missing exam records. Write down what you recall about the first change without guessing an onset date. The case-group schedule and an initial online inquiry do not replace a claim-specific filing check.

Scientific evidence for this case

Ozempic and GLP-1 gut injury claims · JAMA Ophthalmology · 2024Cohort

Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide

Type 2 diabetes patients: 8.9% NAION risk on semaglutide vs 1.8% on non-semaglutide medications

Ozempic and GLP-1 gut injury claims · JAMA · 2023Cohort

Risk of Gastrointestinal Adverse Events Associated With GLP-1 Receptor Agonists for Weight Loss

Gastroparesis hazard ratio: 3.67 (95% CI 1.15-11.90)

Ozempic and GLP-1 gut injury claims · Clinical Gastroenterology and Hepatology · 2024Meta-analysis

GLP-1 Receptor Agonists and Gallbladder Disease: A Systematic Review of Randomized Controlled Trials

37% increased relative risk of gallbladder disease across 76 RCTs

Find out where you stand.

The review is free and private. Asking for it doesn’t commit you to anything.

Register your interest

Sources

  1. Court GI case-group overviewCourt GI case-group overview · court
  2. August 28, 2026 GI hearing scheduleAugust 28, 2026 GI hearing schedule · court
  3. NAION transfer orderNAION transfer order · court
  4. Sodhi original gastrointestinal cohort studySodhi original gastrointestinal cohort study · study
  5. FDA Ozempic prescribing information, May 2026FDA Ozempic prescribing information, May 2026 · regulator
  6. NIDDK gastroparesis definitionNIDDK gastroparesis definition · regulator
  7. NIDDK gastroparesis diagnosisNIDDK gastroparesis diagnosis · regulator
  8. NIDDK symptoms and care warningsNIDDK symptoms and care warnings · regulator
  9. ABA Model Rule 1.5 fee questionsABA Model Rule 1.5 fee questions
  10. Court filing-time guideCourt filing-time guide · court
  11. Federal covered-record access ruleFederal covered-record access rule · regulator
  12. U.S. Courts civil-case guideU.S. Courts civil-case guide · court
  13. FDA Issues Class I Recall for Omnipod 5 Insulin Pods Over Leak Riskapi.fda.gov · Jul 14, 2026 · regulator
  14. NANOS: Non-Arteritic Anterior Ischemic Optic Neuropathy
  15. MedlinePlus eye care
  16. Hathaway et al., semaglutide and NAION, original author abstract and metadata
  17. MDL3163 Case Management Order14, August27,2026MDL3163 Case Management Order14, August27,2026 · court
  18. EMA PRAC meeting highlights June2–5,2025, notice June6,2025EMA PRAC meeting highlights June2–5,2025, notice June6,2025 · regulator

Checked against 17 primary sources by People's Justice editors · Updated

How we make money

People's Justice research team · Updated Oct 4, 2026